The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL12 2022 | The importance of individualizing treatment approaches in HL to improve patient outcomes
Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, comments on the importance of individualizing treatment approaches in Hodgkin lymphoma (HL), and the value of novel agents in this space. Dr Bröckelmann also highlights the importance of reducing patient exposure to chemotherapy, and better understanding mechanisms of resistance to anti-PD1 inhibitors to provide options for patients with relapsed disease. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: BeiGene, Bristol-Myers Squibb, MSD, Takeda
Research funding: BeiGene, Bristol-Myers Squibb, MSD, Takeda
Advisory boards: Takeda
Speakers’ bureau: BeiGene, MSD
